Neuroject ApS: Financial statements 2024
CVR: 43712241
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
Neuroject ApS (CVR 43712241) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK 502,661 and a net result of DKK 67,834 compared with DKK -32,693 the year before. Equity in the 2024 report amounted to DKK 75,141. The solvency ratio was 35.4%. The company had 1 employee in the financial year.
- Gross Profit
- DKK 502,661
- Profit/Loss
- DKK 67,834
- Equity
- DKK 75,141
- Total Assets
- DKK 212,152
- Employees
- 1
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
Neuroject ApS has published its annual report for 2023. Gross profit came to DKK -25,158, and the net result was DKK -32,693.
About Neuroject ApS
Neuroject ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2022. The company is registered under the industry Virksomhedsrådgivning og anden ledelsesrådgivning. The management consists of Brian Taammoli. The company is owned by Neural Stem Cell ApS. The company has 1 employee (2026). In 2025, the company reported a gross profit of DKK 326,576 and a net result of DKK -346,903 compared with DKK 67,834 the year before. Equity in the 2025 report amounted to DKK -271,762.